348 related articles for article (PubMed ID: 10953327)
1. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
Pu Q; Bianchi P; Bezwoda WR
Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
[TBL] [Abstract][Full Text] [Related]
2. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
Pu QQ; Bezwoda WR
Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
[TBL] [Abstract][Full Text] [Related]
3. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
4. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.
Friedman HS; Skapek SX; Colvin OM; Elion GB; Blum MR; Savina PM; Hilton J; Schold SC; Kurtzberg J; Bigner DD
Cancer Res; 1988 Oct; 48(19):5397-402. PubMed ID: 3416297
[TBL] [Abstract][Full Text] [Related]
5. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
7. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair.
Panasci L; Paiement JP; Christodoulopoulos G; Belenkov A; Malapetsa A; Aloyz R
Clin Cancer Res; 2001 Mar; 7(3):454-61. PubMed ID: 11297233
[TBL] [Abstract][Full Text] [Related]
8. Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity.
Robson CN; Lewis AD; Wolf CR; Hayes JD; Hall A; Proctor SJ; Harris AL; Hickson ID
Cancer Res; 1987 Nov; 47(22):6022-7. PubMed ID: 3664506
[TBL] [Abstract][Full Text] [Related]
9. Expression of a rat glutathione-S-transferase complementary DNA in rat mammary carcinoma cells: impact upon alkylator-induced toxicity.
Schecter RL; Alaoui-Jamali MA; Woo A; Fahl WE; Batist G
Cancer Res; 1993 Oct; 53(20):4900-6. PubMed ID: 8402679
[TBL] [Abstract][Full Text] [Related]
10. Transport, metabolism, and DNA interaction of melphalan in lymphocytes from patients with chronic lymphocytic leukemia.
Panasci L; Henderson D; Torres-Garcia SJ; Skalski V; Caplan S; Hutchinson M
Cancer Res; 1988 Apr; 48(7):1972-6. PubMed ID: 3349471
[TBL] [Abstract][Full Text] [Related]
11. Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia.
Christodoulopoulos G; Malapetsa A; Schipper H; Golub E; Radding C; Panasci LC
Clin Cancer Res; 1999 Aug; 5(8):2178-84. PubMed ID: 10473103
[TBL] [Abstract][Full Text] [Related]
12. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
[TBL] [Abstract][Full Text] [Related]
13. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line.
Batist G; Torres-Garcia S; Demuys JM; Greene D; Lehnert S; Rochon M; Panasci L
Mol Pharmacol; 1989 Aug; 36(2):224-30. PubMed ID: 2770701
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
Papadopoulou MV; Ji M; Khan SH; Bloomer WD
Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738
[TBL] [Abstract][Full Text] [Related]
15. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
Shellard SA; Hosking LK; Hill BT
Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
[TBL] [Abstract][Full Text] [Related]
16. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of melphalan resistance developed in vitro in human melanoma cells.
Parsons PG; Carter FB; Morrison L; Regius Mary Sister
Cancer Res; 1981 Apr; 41(4):1525-34. PubMed ID: 6163526
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of a melphalan-resistant human multiple myeloma cell line.
Bellamy WT; Dalton WS; Gleason MC; Grogan TM; Trent JM
Cancer Res; 1991 Feb; 51(3):995-1002. PubMed ID: 1988143
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle-dependent cytotoxicity of alkylating agents: determination of nitrogen mustard-induced DNA cross-links and their repair in Chinese hamster ovary cells synchronized by centrifugal elutriation.
Murray D; Meyn RE
Cancer Res; 1986 May; 46(5):2324-9. PubMed ID: 3697977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
